Sanofi SA is to further extend its investment in messenger RNA (mRNA) technology with a bid to acquire Translate Bio Inc, a company with which it has had an mRNA vaccine collaboration since June 2018. The French company is offering $38 per share in cash for Translate Bio, giving a transaction value of $3.2 billion. Sanofi will finance the deal internally.
